Wall Street analysts predict that Strongbridge Biopharma PLC (NASDAQ:SBBP) will announce ($0.41) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Strongbridge Biopharma PLC’s earnings, with estimates ranging from ($0.48) to ($0.37). Strongbridge Biopharma PLC posted earnings of ($0.36) per share during the same quarter last year, which would suggest a negative year over year growth rate of 13.9%. The company is expected to announce its next earnings report on Friday, December 22nd.

According to Zacks, analysts expect that Strongbridge Biopharma PLC will report full year earnings of ($2.66) per share for the current fiscal year. For the next financial year, analysts anticipate that the business will post earnings of ($1.30) per share, with EPS estimates ranging from ($1.65) to ($1.01). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Strongbridge Biopharma PLC.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.34). The business had revenue of $1.53 million during the quarter, compared to analyst estimates of $0.84 million.

A number of brokerages have commented on SBBP. Zacks Investment Research downgraded shares of Strongbridge Biopharma PLC from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. initiated coverage on shares of Strongbridge Biopharma PLC in a research note on Thursday, August 10th. They set an “outperform” rating and a $12.00 price objective on the stock. Finally, ValuEngine downgraded shares of Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research note on Monday. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $11.94.

Shares of Strongbridge Biopharma PLC (NASDAQ SBBP) traded down 18.67% during trading on Wednesday, reaching $6.10. The company’s stock had a trading volume of 1,807,975 shares. The stock’s market cap is $215.54 million. The stock has a 50-day moving average of $6.88 and a 200-day moving average of $5.68. Strongbridge Biopharma PLC has a 52-week low of $2.00 and a 52-week high of $8.85.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Strongbridge Biopharma PLC (SBBP) to Post -$0.41 Earnings Per Share” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/04/zacks-analysts-anticipate-strongbridge-biopharma-plc-sbbp-to-post-0-41-earnings-per-share.html.

Hedge funds have recently added to or reduced their stakes in the stock. Broadfin Capital LLC grew its position in shares of Strongbridge Biopharma PLC by 3.0% in the first quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock valued at $14,163,000 after purchasing an additional 87,125 shares during the period. Northern Trust Corp acquired a new stake in shares of Strongbridge Biopharma PLC in the second quarter valued at about $1,462,000. Nexthera Capital LP acquired a new stake in shares of Strongbridge Biopharma PLC in the second quarter valued at about $477,000. Vanguard Group Inc. acquired a new stake in shares of Strongbridge Biopharma PLC in the second quarter valued at about $474,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in shares of Strongbridge Biopharma PLC in the second quarter valued at about $449,000. Institutional investors own 63.65% of the company’s stock.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma PLC (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.